1b/2

Menarini Group Presents New Data from the Phase 1b/2 ELEVATE Study of Elacestrant in Combination with Capivasertib in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Encouraging safety and preliminary efficacy analysis from the elacestrant and capivasertib Phase 1b regimen of the ELEVATE study will be presented.The…

2 weeks ago

Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026

February 23, 2026 17:10 ET  | Source: Kyntra Bio FG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen…

4 months ago